CHAPTERS
- 0:00 – 0:46
From a scheduling mishap to a global trauma mission
Joe explains how a last-minute change (and Duncan Trussell’s emergency root canal) turned the planned appearance into a one-on-one conversation. Rick Doblin arrives straight from Ukraine, framing the episode around trauma response and psychedelic-assisted therapy worldwide.
- •Unexpected booking chain leads Rick onto JRE
- •Doblin just returned from Ukraine
- •Goal: bring psychedelic-assisted therapy to high-trauma areas
- •Sets the tone: policy, science, and humanitarian need
- 0:46 – 3:54
Ukraine: training clinicians amid war and restrictive drug laws
Doblin describes training 55 Ukrainian psychiatrists and therapists in Lviv while air-raid sirens blare in the background. He highlights Ukraine’s enormous trauma burden and the legal barriers that still prevent Schedule I research there.
- •MDMA-assisted therapy training for Ukrainian clinicians
- •Schedule I rules block even basic psychedelic research
- •Draft legislation signals potential legal change
- •Emotional impact of mass graves and visible wartime loss
- 3:54 – 4:49
Taking the model to Beirut and other under-resourced trauma zones
Doblin outlines plans to speak in Lebanon and explore the possibility of initiating MDMA research there. He clarifies he’s speaking personally (not for MAPS or Lykos) and emphasizes philanthropy as the near-term engine for global expansion.
- •Beirut visit: American University of Beirut and business group invitation
- •Potential pathway for MDMA research in Lebanon
- •Doblin distinguishes personal work vs MAPS/Lykos positions
- •Philanthropy as the next-step funding mechanism
- 4:49 – 6:11
Why progress feels so slow: MDMA’s path from 1982 to criminalization
Joe presses on the “snail’s pace” of acceptance, and Doblin traces the arc from his first MDMA experience in 1982 through its 1985 emergency scheduling. They discuss how MDMA moved from therapy circles to “ecstasy” club culture, accelerating backlash.
- •MDMA used quietly in therapy circles before mainstream leak
- •1985 emergency scheduling and the shift to ‘ecstasy’
- •Dallas ‘Starck Club’ era and pop-cultural spread
- •Anecdotal outcomes vs institutional resistance
- 6:11 – 9:10
Celebrity culture, psychedelics, and changing minds (Larry Hagman stories)
A tangent becomes a point: public figures can normalize psychedelic benefits. Doblin shares how Larry Hagman’s LSD therapy experience and public comments helped shift perceptions—and how relationships like these supported MAPS.
- •Larry Hagman’s LSD therapy and CNN moment
- •Story: police cancel a club bust due to Hagman’s presence
- •Doblin’s personal connection and humor (the ‘genie bong’)
- •Public narratives can soften stigma and open dialogue
- 9:10 – 14:21
MAPS origin story and the DEA legal battle: winning twice, losing the war
Doblin explains how administrative and appeals-court fights shaped MAPS’s strategy: the DEA wouldn’t make MDMA a medicine, so they had to go through the FDA. He also recounts the revelation that the initial emergency scheduling was procedurally invalid.
- •MAPS founded in 1986 during peak drug-war politics
- •Administrative law judge recommends Schedule III; DEA refuses
- •Appeals-court back-and-forth leads to standards resembling FDA approval
- •Emergency scheduling authority problem: early busts dismissed
- •Strategic pivot: nonprofit drug development funded by donations
- 14:21 – 18:57
Drug war harms and policy whiplash: from ‘crack babies’ panic to Portland
Doblin uses his father’s pediatric research to show how stigma and criminalization push people away from help. Joe and Rick debate the pitfalls of localized decriminalization—Portland and Zurich’s “Needle Park”—and why humane approaches must be scalable and structured.
- •‘Crack babies’ narrative vs findings: poverty/malnutrition effects dominate
- •Fear of arrest/child removal deters pregnant women from treatment
- •Portland’s decriminalization backlash and public disorder
- •Zurich ‘Needle Park’: humane intent overwhelmed by drug tourism
- •Need for system-wide solutions, not isolated experiments
- 18:57 – 21:30
Bridges to the mainstream: military/veterans, ibogaine, and bipartisan credibility
They argue that veterans and conservative leaders can function as cultural “bridges” that de-stigmatize psychedelics. Rick Perry, Brian Hubbard, and Morgan Luttrell become examples of how trauma recovery stories translate into political momentum.
- •Veteran outcomes (ibogaine) reshape conservative viewpoints
- •Rick Perry and bipartisan figures featured at Psychedelic Science conference
- •Traumatic brain injury recovery signals broader neurological potential
- •‘Bridge’ theme: shifting the binary ‘drugs are for losers’ narrative
- 21:30 – 25:38
What makes psychedelic therapy work: set/setting, integration, and neuroplasticity
Doblin emphasizes that clinics must pair compounds with skilled therapy, preparation, and integration—contrasting with many ketamine clinics that skip therapy. He introduces the neuroscience angle: psychedelics reopening “critical periods” of plasticity where lasting change is more achievable.
- •Therapy context is the intervention—not ‘take this pill’
- •Integration and next-day support as part of the protocol
- •Gül Dölen’s ‘critical periods’ framework and long-lasting plasticity
- •Ibogaine’s extended window may last months
- •Why ‘non-psychedelic psychedelics’ appeal to some use-cases
- 25:38 – 40:01
Non-psychedelic psychedelics in practice: cluster headaches and Bromo-LSD
Doblin tells the origin story of Cluster Busters and early evidence that LSD/psilocybin can interrupt cluster headache cycles. Attempts to avoid stigma led researchers to test Bromo-LSD—only to find it worked even better—yet funding and regulatory inertia still block widespread access.
- •Cluster headaches improved via psychedelics reported by patients
- •Harvard reluctance (legacy stigma) slows direct psychedelic trials
- •Bromo-LSD chosen as a ‘non-psychedelic’ alternative
- •Surprise result: Bromo-LSD works better at higher non-intoxicating doses
- •Frustration: promising treatment stalled for lack of funding
- 40:01 – 54:11
Ceremony, rites of passage, and how culture shapes outcomes
The conversation shifts to how societies integrate altered states responsibly—ayahuasca churches, the Native American Church, and ceremonial use even among youth. Doblin recounts how his bar mitzvah felt like a failed rite of passage, and how LSD later provided the transformative ‘threshold’ experience he expected.
- •Ceremonial context vs abuse: different risk profiles
- •Native American Church peyote ceremony example (child-appropriate dosing)
- •Joe rethinks the value of ritual and rites of passage
- •Doblin’s bar mitzvah story and LSD as a personal rite of passage
- •‘Iron law of prohibition’: bans drive stronger, riskier consumption patterns
- 54:11 – 1:07:18
Scaling treatment: VA timelines, couples work, and the move toward group MDMA therapy
Doblin details how long it took to get MDMA therapy into the VA, then explains why couples-based approaches can outperform individual-only models. With PTSD at population scale, he describes emerging research on group therapy models (VA, Australia, Israel) and the tradeoffs between depth and peer-supported integration.
- •25-year effort: offering VA funding in 1995 to first VA-administered MDMA in 2021
- •DOD funding for active-duty trials and therapy-style comparisons
- •Cognitive Behavioral Conjoint Therapy: improves PTSD and relationship strength
- •Group therapy pilots (Portland VA) and separate cohorts for sexual trauma vs combat trauma
- •Israel study planned as direct individual vs group comparison to reduce cost and scale care
- 1:07:18 – 1:23:28
FDA rejection, the double-blind problem, and what approval could take next
Doblin explains why MDMA-assisted therapy was not approved despite strong Phase 3 outcomes: concerns about functional unblinding, bias, and trial design communication failures. He lays out the fork ahead—possible near-term approval with post-marketing requirements vs a new Phase 3 trial that could add years.
- •Advisory committee and FDA vote ‘no’ (August, prior year)
- •Core methodological challenge: blinding in psychedelic trials
- •MAPS Phase 2 dose-ranging reveals low-dose can worsen comfort in PTSD
- •Phase 3 design: inactive placebo + independent blinded raters (CAPS via telemedicine)
- •Possible outcomes: approval within ~6 months vs new Phase 3 adding ~3.5 years
- •Efficacy highlights: ~2/3 to ~3/4 lose PTSD diagnosis; high responder rates; low dropout
- 1:23:28 – 1:34:42
Why Doblin kept going: a guiding dream, privilege as obligation, and consciousness vs catastrophe
Doblin shares a formative dream linking Holocaust survival, human dehumanization, and the mission to restore psychedelics as tools for empathy and interconnectedness. He reflects on using privilege for long-term change and frames the moment as a race between expanding consciousness and technological catastrophe.
- •Dream narrative: Holocaust ‘saved for a purpose’ message to study psychedelics
- •Personal early missteps: ‘more drugs = faster evolution’ and getting ungrounded
- •Privilege and responsibility: revolutions often start with the privileged (Primo Levi)
- •‘Consciousness vs catastrophe’ and the need for cultural maturation alongside tech
- •Psychedelic renaissance continues even amid institutional setbacks
- 1:34:42 – 2:08:54
Suppression through history, shadow projection, and the importance of context
They connect modern drug policy to centuries of suppression—Eleusinian Mysteries, gatekeeping institutions, colonial crackdowns—and discuss why psychedelics aren’t automatically ‘good’ without context. Doblin ties in Jung’s concept of shadow projection and recounts intense DMT/ketamine insights about collective responsibility and mass psychology.
- •Eleusinian Mysteries and institutional gatekeeping of direct spiritual experience
- •Nixon-era admissions (Ehrlichman) and propaganda as political control
- •Context matters: examples of psychedelics used in harmful cultures (berserkers) and hierarchy (some church structures)
- •Jung: withdrawing shadow projection as a social/political act
- •Doblin’s DMT ‘Hitler is part of me’ insight and ketamine vision of mass power dynamics
- •Parallel tracks: medicalization + drug policy reform + honest drug education
- 2:08:54 – 2:14:11
Psychedelic Science 2025: conference details, global access, and closing reflections
Doblin previews Psychedelic Science 2025 in Denver: hundreds of speakers, multiple stages, music programming, and networking across the psychedelic ecosystem. They close by discussing inclusion of law enforcement and international work in trauma zones, ending on persistence and long-term, multi-generational goals.
- •Conference: June 16–20 in Denver, ~500 speakers, multiple tracks/stages
- •Website and registration details (discount code mentioned)
- •‘Music is the Bridge’ and curated therapeutic music approaches
- •Cross-training future therapists across multiple compounds (not competition)
- •Welcoming ‘feds’ and police/EMT/prison guard trauma as a priority population
- •Doblin’s global plan: Ukraine, Beirut, Africa, Rwanda; optimism despite delays
